This is a multi-part message in MIME format.
--part0_897571045_boundary
Content-ID: <[log in to unmask]>
Content-type: text/plain; charset=US-ASCII
To Listserv Friends, from Robin Elliott (exec, dir. PDF):
I recently sent a note to Ms. Herman on her interesting and thoughtful
postings on "PWP numbers." She thought my comment might merit wider viewing.
Here t'is ...
--part0_897571045_boundary
Content-ID: <[log in to unmask]>
Content-type: text/plain;
name="CSTST981"
Content-transfer-encoding: quoted-printable
Content-disposition: inline
Subj:=09Numbers
Date:=0998-06-11 07:59:10 EDT
From:=09PDF CPMC
To:[log in to unmask]
CC:=09mtuchman@EARTHLI, [log in to unmask], HOFFHEIMER
If you will e-mail me your mailing address, I will be happy to send you a
copy of a cost study (of PD) we recently commissioned at the PDF. It
included a review of 19 epidemiological studies of incidence and prevalan=
ce.
My advice: don't sweat it. None of the available studies are projectible=
to
the entire US (several are from overseas) and those that are the most
projectible show numbers from the low- to mid- hundreds of thousands. NI=
H
estimates about a half million and the drug companies (who have a very
special interest in knowing these numbers) have a similar estimate. Beca=
use
we know that there is a high misdiagnosis rate in PD patients (30 percent=
?)
and because there are probably tens of thousands out there in the hinterl=
ands
who never present for a diagnosis, we believe we are entitled to suggest =
a
higher end to the range--hence the common usage at the PDF: "as many as o=
ne
million."
We also need to present a more-or-less unanimous figure politically, and =
the
"one million" is pretty well stuck in the public perception. I would cou=
nsel
strongly against going higher ("one and a half" ... "two million or more"=
...
I have seen both on the Internet recently). Exaggeration too far beyond
known facts and scientific consensus isn't good PR. For those who want t=
he
numbers, those we have (in my view) are already quite powerful enough.
I was interested in your comments and am sharing them with the fellow who=
did
our desk research on the cost study. Good and provocative thinking.
- robin elliott, executive director, Parkinson's Disease Foundation
--part0_897571045_boundary--
